




NeuroNEXT Network


Standard Operating Procedure (SOP) Document Development and Change Control Version 3.0 SOP NN GA 103

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

Signature and Date: <small>DocuSigned by Christopher Coffey</small>  I approve this document 14-Feb-2023 12:47:52 PM PST <small>C68AC8DD80334CF982AED1200765F147</small> 14-Feb-2023
Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)
Signature and Date: <small>DocuSigned by Merit Cudkowicz</small>  I approve this document 13-Feb-2023 8:13:12 AM EST <small>9F8FE4180E504C6AB0A67B835E80C644</small> 13-Feb-2023
Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)
Signature and Date: <small>DocuSigned by Marianne Chase</small>  I approve this document 13-Feb-2023 8:52:02 AM EST <small>58FE690F6BCA4F2390E3DA15BCE3F578</small> 13-Feb-2023
Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)

Signature and Date:

DocuSigned by DIXIE ECKLUND
 | I approve this document
13-Feb-2023 | 9:56:32 AM PST
7006AF622EFC40B6A067A08EC02591B6

13-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Signature and Date:

DocuSigned by Stacey Grabert
 | I approve this document
22-Feb-2023 | 11:37:27 AM EST
60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon
 | I approve this document
13-Feb-2023 | 11:14:19 AM PST
72C6AAFD8CC4485582ACA0700072901A

13-Feb-2023

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

**NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR
DOCUMENT DEVELOPMENT AND CHANGE CONTROL**

1. POLICY

The NeuroNEXT Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) will ensure that critical documents are developed, approved, and modified in a manner that promotes systematic document development and change control. Substantive changes to critical documents constitute a revision, and may require a formal approval process.

For version-controlled critical documents such as clinical protocol and consent forms that originate with the CCC and/or DCC, the NeuroNEXT Network requires that:

- only the currently approved version of a document is in use at any time;
- new documents are written using established templates as models where feasible and appropriate;
- all new or revised critical documents undergo review by appropriate personnel;
- changes to documents are properly incorporated and tracked;
- draft documents are versioned with a decimal number (e.g. 0.1), and the decimal is increased with each revision;
- final documents are versioned with a whole number (e.g.1.0); and
- final documents are reviewed and approved by the appropriate NeuroNEXT personnel.

Clinical protocols and protocol amendments (if applicable to a study) must be signed by the Protocol Principal Investigator (PPI) and the Directors of the CCC and DCC. Approval of other study documents may be delegated by the Sponsor to the CCC, DCC, and/or the Study Team. The Study Team defines which documents may have delegated authority for review and signature approval and which may not.

Non-controlled documents, such as checklists, are management tools that do not carry regulatory weight and may require less rigorous change control.

The CCC and/or DCC maintain(s) complete files of all current and obsolete version-controlled documents and update(s) document revision histories (e.g. table of modifications or change document), if applicable.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E (R2). The policies and procedures described in this SOP apply to the NeuroNEXT Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research within the Network regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

Each Study Team is responsible for developing team-specific documents and forms, using available templates where feasible and appropriate, and for following document development and change control procedures for version-controlled documents.

The CCC and/or DCC is/are responsible for maintaining complete files of all current and obsolete version-controlled documents, and for updating document revision histories, if applicable.

The responsibility to conduct any or all of these activities may be delegated at the discretion of the Sponsor to the NeuroNEXT CCC and/or DCC or to their subcontractors. Those individuals and entities take on responsibility for meeting regulatory requirements on behalf of the Sponsor, but the Sponsor has the ultimate responsibility and must therefore supervise those delegated activities effectively.

4. APPLICABLE REGULATIONS AND GUIDELINES

21 CFR 312.50	General Responsibilities of Sponsors
21 CFR 312.57	Recordkeeping and Record Retention
ICH E6, 2.13	The Principles of ICH GCP
ICH E6, 5.1	Quality Assurance and Quality Control
ICH E6, 5.5	Trial Management, Data Handling and Recordkeeping

5. REFERENCES TO OTHER APPLICABLE SOPS

NN GA 101	Development and Maintenance of SOPs
NN GA 102	SOP Training
NN RA 202	Trial Master File Maintenance
NN PM 501	Communication

6. ATTACHMENTS AND REFERENCES

NN GA 103 – A	Document History
---------------	------------------

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CCC	Clinical Coordinating Center at Massachusetts General Hospital
DCC	Data Coordinating Center at The University of Iowa
FDA	U.S. Food and Drug Administration
GCP	Good Clinical Practices
ICH	International Council for Harmonisation
PPI	Protocol Principal Investigator
SOP	Standard Operating Procedure

8. SPECIFIC PROCEDURES

A. Development and Approval Procedures for Controlled Documents

#	Who	Task	Attachment	Related SOP
1.	CCC / DCC Leadership, PPI	Determine the need for a new version-controlled document (e.g., new SOP, clinical study materials, protocol).		
2.	CCC / DCC Leadership, PPI	Determine which individual will draft the first version of the new document and who must review and approve the draft of the new document.		
3.	CCC / DCC / Study Team designee	Use a template, when available, to initiate a new draft document.		
4.	CCC / DCC / Study Team designee	Circulate the draft as version 0.1 or a similar designation, and secure comments/suggestions from appropriate reviewers.		
5.	Reviewers	Provide edits or comments if needed, and re-version the document to the next incremental decimal with each subsequent review (e.g. 0.2, 0.3).		
6.	CCC / DCC / Study Team designee	Discuss and resolve any conflicting comments, and prepare the document for approval.		
7.	CCC / DCC / Study Team designee	Circulate the final draft to all signatories and request signatures to indicate approval of the final draft.		
8.	Study Team Signatories	Approve final draft using a signature page or by email confirmation, as appropriate.		
9.	CCC / DCC / Study Team designee	Give all newly-approved documents a version number (e.g. 1.0), an issue date, and an effective date (to be 30 calendar days after the issue date).		
10.	CCC / DCC / Study Team designee	Retain original document and corresponding Change Control Document as appropriate, and ensure proper training and review of document, if applicable.		
11.	CCC / DCC / Study Team designee	Update related indices (e.g., SOP List, Forms List) to reflect the addition of a new document or changes to the name of an existing document, if applicable.		

B. Change Procedures for Controlled Documents

#	Who	Task	Attachment	Related SOP
1.	CCC / DCC Leadership, PPI	Review documents and forms periodically or as needed by circumstances (e.g. new regulation).		
2.	CCC / DCC / Study Team designee	If revisions are not needed, indicate review on a Change Control Document, if applicable.		

#	Who	Task	Attachment	Related SOP
3.	CCC / DCC / Study Team designee	If revisions are needed, make the change(s) and circulate the revised draft (with revisions tracked). Document versioning increases incrementally by a decimal number (1.1, 1.2, etc.) for each revised draft document.		
4.	CCC / DCC / Study Team designee	Continue to give updated and revised documents a new version number, until all revisions are incorporated and ready for final signatures.		
5.	CCC / DCC / Study Team designee	Version the new document with the next consecutive whole number (2.0, 3.0, etc.), circulate to all signatories, and assign the issue date and the effective date.		
6.	CCC / DCC / Study Team designee	If applicable, create a table of modifications or a change document.		
7.	CCC / DCC / Study Team designee	Move obsolete documents to an archive file.		

C. Controlled Document Implementation

#	Who	Task	Attachment	Related SOP
1.	CCC / DCC / Study Team designee	As appropriate, notify all affected parties and regulatory authorities (if applicable) about changes to version-controlled documents, and provide new versions of documents to these parties.		
2.	CCC / DCC / Study Team designee	Train all affected personnel on the use of the new or revised document, if applicable.		NN GA 102
3.	CCC / DCC / Study Team designee	Record that document training was received by all affected personnel.		

Certificate Of Completion

Envelope Id: C0B82582FF0C4F50B2A42D9BC6A082EA Status: Completed
Subject: Complete with DocuSign: NN GA 103 Document Development and Change Control v3.0.docx
Source Envelope:
Document Pages: 6 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 73.159.130.82
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/13/2023 8:08:10 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey
christopher-coffey@uiowa.edu
Security Level: Email, Account Authentication (Required), Login with SSO

Signature

Christopher Coffey

Timestamp

Sent: 2/13/2023 8:11:17 AM
Viewed: 2/14/2023 3:47:43 PM
Signed: 2/14/2023 3:47:55 PM

Signature Adoption: Pre-selected Style
Signature ID:
C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:

Accepted: 2/14/2023 3:47:43 PM
ID: 10babfe0-27af-42fa-ba3f-fd910544e14f

DIXIE ECKLUND
dixie-ecklund@uiowa.edu
Security Level: Email, Account Authentication (Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document
13-Feb-2023 | 9:56:32 AM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/13/2023 8:11:17 AM
Viewed: 2/13/2023 12:55:17 PM
Signed: 2/13/2023 12:56:40 PM

Signature Adoption: Drawn on Device
Signature ID:
7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:

Accepted: 2/13/2023 12:55:17 PM
ID: 35c2127d-99cd-4bca-aa4d-26c233428f0d

Signer Events**Signature****Timestamp**

Joan Ohayon
 ohayonj@ninds.nih.gov
 Security Level: Email, Account Authentication
 (Required)

Joan Ohayon

Sent: 2/13/2023 8:11:18 AM
 Viewed: 2/13/2023 2:13:48 PM
 Signed: 2/13/2023 2:14:23 PM

Signature Adoption: Pre-selected Style
 Signature ID:
 72C6AAFD-8CC4-4855-82AC-A0700072901A
 Using IP Address: 71.178.185.120

With Signing Authentication via DocuSign password
 With Signing Reasons (on each tab):
 I approve this document

Electronic Record and Signature Disclosure:
 Accepted: 2/13/2023 2:03:22 PM
 ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase
 MCHASE@mgh.harvard.edu
 Sr Director, Clinical Trial Operations
 Insight OBO The Massachusetts General Hospital
 Security Level: Email, Account Authentication
 (Required)

Marianne Chase


Sent: 2/13/2023 8:11:18 AM
 Viewed: 2/13/2023 8:51:42 AM
 Signed: 2/13/2023 8:52:05 AM

Signature Adoption: Pre-selected Style
 Signature ID:
 58FE690F-6BCA-4F23-90E3-DA15BCE3F578
 Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password
 With Signing Reasons (on each tab):
 I approve this document

Electronic Record and Signature Disclosure:
 Not Offered via DocuSign

Merit Cudkowicz
 cudkowicz.merit@mgh.harvard.edu
 Chief of Neurology
 Security Level: Email, Account Authentication
 (Required), Logged in


DocuSigned by Merit Cudkowicz

 I approve this document
 13-Feb-2023 | 8:13:12 AM EST
 9F8FE4180E504C6AB0A67B835E80C644

Sent: 2/13/2023 8:11:18 AM
 Viewed: 2/13/2023 8:13:02 AM
 Signed: 2/13/2023 8:13:14 AM

Signature Adoption: Pre-selected Style
 Signature ID:
 9F8FE418-0E50-4C6A-B0A6-7B835E80C644
 Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password
 With Signing Reasons (on each tab):
 I approve this document

Electronic Record and Signature Disclosure:
 Accepted: 2/13/2023 8:13:02 AM
 ID: ddd0047f-c6fd-4842-a4ce-f3819a0de5df

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/13/2023 8:11:19 AM Viewed: 2/22/2023 11:37:17 AM Signed: 2/22/2023 11:37:30 AM
Electronic Record and Signature Disclosure: Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/13/2023 8:11:19 AM
Certified Delivered	Security Checked	2/22/2023 11:37:17 AM
Signing Complete	Security Checked	2/22/2023 11:37:30 AM
Completed	Security Checked	2/22/2023 11:37:30 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.